Loading stock data…
EW
$82.63-1.19 (-1.42%)
Market ClosedLast close Jul 24
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Edwards Lifesciences Corporation in the Healthcare sector is trading at $82.63 with a market capitalization of $51.1B. Wall Street consensus targets $100.36 (25 analysts), implying a +21.5% move over the next 12 months. The stock is currently 14% below its 52-week high of $96.29, remaining 1.0% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 9 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +21.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 9) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.65B↑ | $1.57B↑ | $1.55B↑ | $1.53B↑ | $1.41B |
| Gross Profit | $1.29B↑ | $1.23B↑ | $1.21B↑ | $1.19B↑ | $1.11B |
| Operating Income | $514.70M↑ | $370.30M↓ | $425.10M↓ | $430.90M↑ | $409.90M |
| Net Income | $380.70M↑ | $91.20M↓ | $291.10M↓ | $329.80M↓ | $358.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive re...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$51.10B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
10.58%
Volume
Today's trading volume
9.26M
Recent News
Edwards Lifesciences (EW) Stock Looks Fair On Cash Flow While Earnings Trade At A Premium
Edwards Lifesciences stock sits at an interesting spot for valuation focused investors, with the Discounted Cash Flow (DCF) based intrinsic value estimate suggesting the shares are roughly in line with underlying cash flow assumptions, while the broader checks still point to a stock that does not screen as cheap and has delivered a decline over five years. Over the past 5 years, Edwards Lifesciences has delivered a total return that is down 26.4%, which raises the question of whether the...
Edwards, The 'Cleanest Large-Cap Medtech Story,' Reverses After Quarterly Beat
Edwards Lifesciences stock fell Friday, though the medtech company beat Wall Street's top- and bottom-line expectations.
SpaceX initiated, PayPal upgraded: Wall Street's top analyst calls
SpaceX initiated, PayPal upgraded: Wall Street's top analyst calls
Edwards lifts FY26 growth outlook following steady Q2 performance
Edwards TAVR business contributed the lion’s share of its Q2 revenues at $1.26bn, largely informing its decision to uplift its 2026 revenue growth outlook.
Edwards' Q2 Earnings & Revenues Top Estimates, Stock Rises
EW beats Q2 earnings and revenue estimates as strong TAVR demand, and mitral and tricuspid therapy adoption lift results and guidance.